Amass was founded by Alexander Junge, Henrik Jensen in 2022.

Who are Amass's investors?

Amass's investors include Novo Holdings, Giant Ventures Global Llp, Kost Capital.

Amass

Founded 2022 · 9 employees on LinkedIn · 3 known investors

Find your way into Amass

Paths you didn't know you had: your email and LinkedIn already hold routes to the Amass team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Amass operates an agentic data platform that unifies over 500 million scientific documents — including research literature, patents, clinical trials, regulatory filings, and web sources — into a single engine that returns answers cited to their source. It serves researchers, life science companies, and research institutions through an app, API, and MCP interface, with each claim traceable to underlying evidence.

AI & Machine Learning Biotech Data & Infrastructure

Founders & leadership

Amass was founded in 2022 by Alexander Junge and Henrik Jensen.

Alexander Junge Co-Founder & CTOAlexander Junge is co-founder and CTO of Amass, an agentic data platform unifying scientific documents for life sciences and pharma. Previously, he led machine learning and AI teams at Corti, a healthcare startup, and developed AI-powered medical coding solutions.

Henrik JensenCo-Founder & CEO

Investors · 3

Novo Holdings✓ confirmed by AmassCopenhagen · $1.1M – $54M

How we know: the company's own site · Not right? Tell us

Giant Ventures Global Llplisted by Giant Ventures Global LlpLondon · $10M – $20M

How we know: Giant Ventures Global Llp's portfolio page · a partner's Signal profile · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

Kost Capitallisted by Kost CapitalFrederiksberg

Related companies · 1

OmassOMass is a biotech company that originated as a spinout from Oxford University, developing specialized treatments for patient populations with high unmet medical needs. The company builds integrated development and commercialization capabilities while partnering to advance programs addressing large indications.

Companies working in the same space as Amass.

Frequently asked questions

What does Amass do?: Amass operates an agentic data platform that unifies over 500 million scientific documents — including research literature, patents, clinical trials, regulatory filings, and web sources — into a single engine that returns answers cited to their source. It serves researchers, life science companies, and research institutions through an app, API, and MCP interface, with each claim traceable to underlying evidence.
Who founded Amass?: Amass was founded by Alexander Junge, Henrik Jensen in 2022.
Who are Amass's investors?: Amass's investors include Novo Holdings, Giant Ventures Global Llp, Kost Capital.